Sixty-two percent of those folks lost more than 10 percent of body weight, with additional perks like lower cholesterol
Dec 18, 2025, 08:00 ET CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways 1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment *2 Novo Nordisk continues to build on its 100-year-plus legacy of science and innovation, with potential new treatments in obesity PLAINSBORO, N.J
The dual GLP-1 and GIP activation also influences the hypothalamus, the brain region controlling temperature regulation, potentially amplifying cold sensitivity during early treatment phases
Twice-weekly dosing would create unpredictable serum concentrations, potentially overwhelming GLP-1 receptors and triggering excessive nausea, vomiting, and gastrointestinal distressside effects already common at standard doses
Furthermore, it promotes the migration of CD8+ T cells from the tumor periphery to the tumor core, thereby improving the efficacy of immunotherapy (97)
